Literature DB >> 3257770

B cell stimulatory factor 1 (IL-4) enhances the development of cytotoxic T cells from Lyt-2+ resting murine T lymphocytes.

G Trenn1, H Takayama, J Hu-Li, W E Paul, M V Sitkovsky.   

Abstract

B cell stimulatory factor 1 (BSF-1) (IL-4) was shown to synergize with phorbol esters or with monoclonal anti-TCR antibody in stimulation of the development of CTL from small resting murine T cells. IL-2 also synergized with PMA in such differentiation but was less effective than BSF-1. The combination of these two lymphokines with PMA had the most potent effect on the development of CTL. BSF-1 plus PMA stimulated a significant increase in the intracellular content of N-benzyloxycarbonyl-L-lysine thiobenzylester esterase, a granule-associated biochemical marker, whereas IL-2 plus PMA was only marginally effective. Depletion of L3T4+ cells did not result in the abrogation of these effects. Lyt-2+ T cells that were incubated for 72 h with BSF-1 plus PMA accumulated N-benzyloxycarbonyl-L-lysine thiobenzylester esterase and secreted this intragranular marker after interaction with immobilized anti-T cell receptor mAb. These BSF-1/PMA-stimulated Lyt-2+, L3T4- T cells were also able to kill FcR positive target cells in a retargeting assay with a mAb to murine T3 Ag, providing evidence that BSF-1 plus PMA acted directly on precursors of cytotoxic T cells.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3257770

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  12 in total

1.  Gamma interferon is not required for mucosal cytotoxic T-lymphocyte responses or heterosubtypic immunity to influenza A virus infection in mice.

Authors:  H H Nguyen; F W van Ginkel; H L Vu; M J Novak; J R McGhee; J Mestecky
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

2.  Interleukin-4 diminishes CD8(+) respiratory syncytial virus-specific cytotoxic T-lymphocyte activity in vivo.

Authors:  S Aung; Y W Tang; B S Graham
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

3.  Requirements for activation of CD8+ murine T cells. I. Development of cytolytic activity.

Authors:  D C Cronin; D W Lancki; F W Fitch
Journal:  Immunol Res       Date:  1994       Impact factor: 2.829

4.  Effects of cytokines on in vitro growth of tumor-infiltrating lymphocytes obtained from human primary and metastatic liver tumors.

Authors:  Y Shimizu; S Iwatsuki; R B Herberman; T L Whiteside
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

5.  Activity of CD4+ T-cell clones of type 1 and type 2 in generation of influenza virus-specific cytotoxic responses in vitro.

Authors:  G Palladino; P A Scherle; W Gerhard
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

Review 6.  The antitumor immune response as a problem of self-nonself discrimination: implications for immunotherapy.

Authors:  P Golumbek; H Levitsky; L Jaffee; D M Pardoll
Journal:  Immunol Res       Date:  1993       Impact factor: 2.829

Review 7.  Cytokine-mediated gene therapy for cancer.

Authors:  A R Miller; W H McBride; K Hunt; J S Economou
Journal:  Ann Surg Oncol       Date:  1994-09       Impact factor: 5.344

8.  Endogenously produced IL-4 nonredundantly stimulates CD8+ T cell proliferation.

Authors:  Suzanne C Morris; Stephanie M Heidorn; De'Broski R Herbert; Charles Perkins; David A Hildeman; Marat V Khodoun; Fred D Finkelman
Journal:  J Immunol       Date:  2009-02-01       Impact factor: 5.422

9.  Lack of association between interleukin-4 gene polymorphisms and autoimmune thyroid diseases amongst Taiwanese Chinese.

Authors:  Rong-Hsing Chen; Chwen-Tzuei Chang; Tzu-Yuan Wang; Ching-Chu Chen; Chang-Hai Tsai; Fuu-Jen Tsai
Journal:  Endocrine       Date:  2007-12-05       Impact factor: 3.633

10.  Systemic reduction of interleukin-4 or interleukin-10 fails to reduce the frequency or severity of experimental cytomegalovirus retinitis in mice with retrovirus-induced immunosuppression.

Authors:  Emily L Blalock; Hsin Chien; Richard D Dix
Journal:  Ophthalmol Eye Dis       Date:  2012-09-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.